default author photo

Liangfang Shen

Central South University - Department of Oncology

Changsha , Hunan 410008

China

SCHOLARLY PAPERS

2

DOWNLOADS

161

TOTAL CITATIONS

0

Scholarly Papers (2)

A Recurrence Risk Score Model Evaluating Effects of Postmastectomy Radiotherapy in Breast Cancer Patients with Pathologically Negative Lymph Nodes after Neoadjuvant Chemotherapy: A Multicenter, Retrospective Study

Number of pages: 35 Posted: 26 Aug 2024
Chinese Academy of Medical Sciences - National Cancer Center, affiliation not provided to SSRN, Jilin Cancer Hospital, affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Tianjin Medical University - Tianjin Medical University Cancer Institute and Hospital, Sun Yat-sen University (SYSU), Central South University - Department of Oncology, Government of the People's Republic of China - Xijing Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology
Downloads 50 (1,083,731)

Abstract:

Loading...

Breast Cancer, Neoadjuvant chemotherapy, Pathologically negative lymph node, Recurrence risk score model, Postmastectomy radiotherapy

A Recurrence Risk Score Model Evaluating Effects of Postmastectomy Radiotherapy in Breast Cancer Patients with Pathologically Negative Lymph Nodes after Neoadjuvant Chemotherapy: A Multicenter, Retrospective Study

Number of pages: 31 Posted: 22 May 2024
Chinese Academy of Medical Sciences - National Cancer Center, affiliation not provided to SSRN, Jilin Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, Tianjin Medical University - Tianjin Medical University Cancer Institute and Hospital, Sun Yat-sen University (SYSU), Central South University - Department of Oncology, Government of the People's Republic of China - Xijing Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology, affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Department of Radiation Oncology
Downloads 40 (1,210,354)

Abstract:

Loading...

Breast cancer, Neoadjuvant chemotherapy, Pathologically negative lymph node, Recurrence risk score model, Postmastectomy radiotherapy

2.

Efficacy and Safety of KL-A167 in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Study

Number of pages: 33 Posted: 22 Mar 2022
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Guangdong Pharmaceutical University - Department of Medical Oncology, Sichuan University - Collaborative Innovation Center for Biotherapy, Guangxi Medical University - Department of Respiratory Oncology, Jiangxi Cancer Hospital - Department of Head and neck radiotherapy, Fujian Medical University - Department of Radiation Oncology, Fujian Medical University - Department of Radiation Oncology, Yue Bei People's Hospital - Department of Oncology Radiotherapy, Zhejiang University - Department of Medical Oncology, Nantong Tumor Hospital - Department of Oncology Radiotherapy, Chongqing Medical University - First Affiliated Hospital, The People's Hospital of Guangxi Zhuang Autonomous Region - Department of Head and neck surgery, Guangzhou University of Chinese Medicine - Department of Oncology, Fujian Medical University - Department of Radiation Oncology, Zhengzhou University - Henan Cancer Hospital, Liuzhou Worker’s Hospital - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Anhui Provincial Cancer Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Guangdong Medical University - Department of Oncology, Fudan University - Internal Medicine Oncology, Government of the People's Republic of China - Department of Oncology, Nanchang University - Department of Medical Oncology, Huazhong University of Science and Technology - Department of Oncology, Hebei Medical University - Fourth Hospital, Harbin Medical University - Department of Medical Breast oncology, Nanjing Medical University - Department of Oncology, Shanghai Jiao Tong University (SJTU) - Shanghai General Hospital, Fujian Medical University - Department of Radiation Oncology, Guizhou Medical University (Guiyang Medical University) - Department of Head and Neck oncology, Haikou People’s Hospital - Department of Medical Oncology, Linyi Cancer Hospital - Department of Medical Oncology, Tianjin Medical University - Department of Oncology Radiotherapy, Jilin University (JLU) - Cancer Center, Huazhong University of Science and Technology - Cancer Center, Wenzhou Medical University - Department of Medical Oncology, Yunnan Cancer Hospital, Central South University - Department of Oncology, Central South University - Department of Oncology, Shandong University - Department of Head and Neck neoplasm, Dalian University - Department of Oncology, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Downloads 71 (867,774)

Abstract:

Loading...

KL-A167, nasopharyngeal carcinoma, efficacy, safety, PD-L1, biomarker